Characteristics | Patients, n (%) (n = 262) | Controls, n (%) (n = 270) | P |
---|---|---|---|
Age | Â | Â | Â |
<50 | 8(3.0) | 9(3.3) | 0.729 |
50-59 | 18(6.9) | 20(7.4) | Â |
60-69 | 83(31.7) | 86(31.9) | Â |
70-79 | 123(46.9) | 130(48.1) | Â |
≥80 | 30(11.5) | 25(9.3) |  |
Average age | 70.7 ± 8.4 | 70.2 ± 8.5 |  |
Smoking status | Â | Â | Â |
Nonsmoking | 102 (38.9%) | 109(40.4%) | 0.734 |
smoking | 160(61.1%) | 161(59.6%) | Â |
History of prostate cancer | Â | Â | Â |
Yes | 14(5.3) | 6(2.2) | 0.067 |
No | 248(94.7) | 264(97.8) | Â |
PSA (ng/ml) | Â | Â | Â |
Average concentration | 128.33 ± 634.21 | 2.146 ± 0.954 | <0.001 |
≤10 | 80(30.5) |  |  |
>10 | 182(69.5) | Â | Â |
Gleason score | Â | Â | Â |
≤7 | 72(27.5) |  |  |
>7 | 161(62.5) | Â | Â |
missing | 29(11.0) | Â | Â |
Clinical T Stage | Â | Â | Â |
≤T2 | 93(35.5) |  |  |
>T2 | 156(59.5) | Â | Â |
missing | 13(5.0) | Â | Â |
Agressive status | Â | Â | Â |
Early stage | 72(27.5) | Â | Â |
Advanced stage | 180(68.7) | Â | Â |
missing | 10(3.8) | Â | Â |